Brokerages predict that Gamida Cell Ltd (NASDAQ:GMDA) will report ($0.37) earnings per share (EPS) for the current quarter, Zacks Investment Research reports. Zero analysts have issued estimates for Gamida Cell’s earnings. Gamida Cell posted earnings per share of ($14.23) in the same quarter last year, which would suggest a positive year over year growth rate of 97.4%. The business is expected to announce its next earnings report after the market closes on Wednesday, November 13th.
On average, analysts expect that Gamida Cell will report full-year earnings of ($1.16) per share for the current year. For the next fiscal year, analysts anticipate that the company will post earnings of ($1.31) per share. Zacks Investment Research’s earnings per share averages are a mean average based on a survey of research analysts that follow Gamida Cell.
Several equities analysts have commented on the company. Oppenheimer set a $18.00 target price on Gamida Cell and gave the company a “buy” rating in a research report on Wednesday, August 7th. JMP Securities assumed coverage on Gamida Cell in a research report on Friday, September 20th. They set an “outperform” rating and a $16.00 price objective for the company. Zacks Investment Research downgraded Gamida Cell from a “buy” rating to a “hold” rating in a research report on Wednesday, October 9th. Finally, ValuEngine upgraded Gamida Cell from a “hold” rating to a “buy” rating in a research report on Thursday, August 1st. One analyst has rated the stock with a hold rating and seven have issued a buy rating to the company. The stock currently has a consensus rating of “Buy” and a consensus price target of $16.43.
Gamida Cell stock traded down $0.10 during trading hours on Wednesday, hitting $4.85. The stock had a trading volume of 304 shares, compared to its average volume of 24,554. The company has a quick ratio of 4.47, a current ratio of 4.47 and a debt-to-equity ratio of 0.23. The stock has a market cap of $117.96 million and a price-to-earnings ratio of -0.46. Gamida Cell has a one year low of $2.93 and a one year high of $15.41. The business’s 50 day simple moving average is $4.64 and its 200-day simple moving average is $5.27.
About Gamida Cell
Gamida Cell Ltd. is a clinical stage biopharmaceutical company, which engages in the development of cell therapies that are designed to cure cancer and rare serious hematologic diseases. Its products pipeline include NiCord and NAM-NK. The company was founded by Tony Peled and Menashe Levy in 1998 and is headquartered in Jerusalem, Israel.
See Also: What is the QQQ ETF?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Gamida Cell Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gamida Cell and related companies with MarketBeat.com's FREE daily email newsletter.